- Home
- CAPR
as 07-26-2024 4:00pm EST
Capricor Therapeutics Inc is a United States-based biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy and other medical conditions. The company's development stage product pipeline includes CAP-1002, for Duchenne Muscular Dystrophy Program and COVID-19 Program; CDC-Exosomes (CAP-2003); and Exosome-mRNA vaccine.
| Founded: | 2005 | Country: | United States |
| Employees: | N/A | City: | BEVERLY HILLS |
| Market Cap: | 148.1M | IPO Year: | N/A |
| Target Price: | $21.75 | AVG Volume (30 days): | 558.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.83 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.68 - $8.22 | Next Earning Date: | 08-05-2024 |
| Revenue: | $27,098,247 | Revenue Growth: | 389.30% |
| Revenue Growth (this year): | -9.89% | Revenue Growth (next year): | 172.56% |
Latest Capricor Therapeutics Inc. News
CAPR Breaking Stock News: Dive into CAPR Ticker-Specific Updates for Smart Investing
MT Newswires
25 days ago
Capricor Therapeutics Joins Russell 3000, Russell 2000 Indexes
GlobeNewswire
25 days ago
Capricor Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes
Clinical Trials Arena
a month ago
Capricor’s cell therapy shows three year benefit in DMD patients
GlobeNewswire
a month ago
Capricor Therapeutics Announces Long-Term Benefit of Deramiocel (CAP-1002) in Both Skeletal Muscle and Cardiac Function in the HOPE-2 OLE Study in Duchenne Muscular Dystrophy
GlobeNewswire
a month ago
CORRECTION: Capricor Therapeutics
GlobeNewswire
a month ago
Capricor Therapeutics Announces for the Treatment of Duchenne Muscular Dystrophy
MT Newswires
a month ago
Sector Update: Health Care Stocks Decline Tuesday Afternoon
MT Newswires
a month ago
Capricor Says FDA Grants Pre-BLA Meeting Request for Duchenne Muscular Dystrophy Treatment; Shares Rise
Compare CAPR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CAPR Capricor Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.